Effects of "For-Baby" Supplementation on Young Children's Physical Growth and Diarrhea Episodes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

1200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-20

Study Completion Date

2023-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The LaoBiome Study is a community-based, randomized, placebo-controlled trial with two study arms conducted in Lao People's Democratic Republic. This study aims at providing evidence on impact of For-baby powder supplement on child physical growth, diarrheal incidence, environmental enteric dysfunction, adherence to the intervention, and neuro-behavioural development of: 1) daily administration of For-Baby powder supplements (Intervention Group) and 2) daily administration of micronutrient powder (Placebo-Controlled Group).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia

NCT02257762

Child Malnutrition

UNKNOWN NA

Randomized, Controlled Trial - Lactoferrin Prevention of Diarrhea in Children

NCT00560222

Diarrhea Malnutrition

COMPLETED PHASE3

the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children

NCT05911893

Malnutrition, Child Malnourishment Nutritional Deficiency +1 more

RECRUITING NA

Acceptability of a Multiple Micronutrient-Fortified Lipid-Based Nutrient Supplement for Children Under Two in Cambodia

NCT02257437

Child Malnutrition

COMPLETED NA

Effects of Prebiotics on Metagenomic Diversity and Abundance in Young Children With Acute Malnutrition

NCT06155474

Child Malnutrition

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Probiotics are delivered as multiple micronutrient supplements in a powder package (For-Baby powder's sachet) and add into a single serving of clean water or breast milk and spoon feed the powder to the child 30 minutes before or after food consumption or add to semi-solid or mashed food such as mashed mango, banana and papaya, boiled pumpkin, and boiled egg after the food has been cooked and cooled sufficiently to be eaten (but within 30 minutes of preparation). Recent studies has shown that certain probiotics are extremely useful for the treatment of environmental enteropathy in malnourished children and has significant growth promoting effects. Nonetheless, new studies are needed to better understand the environmental enteropathy and its consequences.

This community-based, randomized, placebo-controlled trial with two groups will be conducted in the community of Luangprabang province in the northern part of Lao PDR.

The study team will enroll a total of 1,200 children, aged 6-23 months into the trial. The children will be randomly assigned one of two groups: 1) intervention group of daily For-Baby powder supplements and 2) control group of daily micronutrient powder supplements. After enrollment, the children will be under the observation for a total of 12 months (52 weeks). The monitored outcomes are the physical growth, diarrheal episodes, motor and intellectual development, gut microbiota and intestinal parasitic infections.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Children Malnutrition

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

The LaoBiome Study is a community-based double blinded randomized controlled trial. Approximately 1,200 infants and young children 6-23 months of age will be enrolled, and individually-randomized to one of two intervention groups of 600 children: 1) daily administration of For-Baby supplement (Intervention Group); 2) daily administration of micronutrient Placebo (Control Group). In both groups, children will remain under observation and receive their assigned supplements for a period of 12 months.

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

The randomization scheme will be generated by an independent Statistician using a computer-generated block randomization scheme, with randomly selected block lengths of 4. Each of the two study arms will be identified by a unique 1-digit code (1, 2). The Institut Pasteur du Laos (IPL) member, unaffiliated with the study, will be responsible for assigning each of the two study codes to an intervention product and communicating this information directly to the product manufacturers. The identity of the treatment codes is stored in sealed envelopes held by the co-principal investigators (PIs) and the statistician. The envelopes will be opened only after statistical analyses of primary outcomes are completed and consensus on the interpretation of results is reached, unless required by one of the IRBs or the Project Steering Committee.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

"For-Baby powder" supplement

For-baby supplements provided as powder containing dry yeast powder, biovita mixed probiotics, synergy probiotics and other nutrients such as glucose, xylitol, chocolate powder, chocolate flavor powder, organic galactose oligosaccharide, chicory extract powder, vegetable Cream substitute, silicon dioxide, milk flavor powder, whole milk powder, zinc oxide, vitamin B12, vitamin B6, enzyme mixed preparation, vitamin C, organic alpha rice powder, folate 0.4mg, thiamine, leucin, isoleucin, valine, glutamine, and magnesium chloride.

Group Type EXPERIMENTAL

"For Baby "supplements provided as powder

Intervention Type DIETARY_SUPPLEMENT

One sachet daily

Micronutrient powder

Micronutrient powder containing containing glucose 236.3mg, xylitol 150mg, chocolate powder 600mg, chocolate flavor powder 45mg, organic galactose oligosaccharide 60mg, chicory extract powder 60mg, vegetable Cream substitute 135mg, silicon dioxide 45mg, milk flavor powder 30mg, whole milk powder 75mg, zinc oxide 11.2mg, vitamin B12 2.6mg, vitamin B6 2mg, enzyme mixed preparation 2mg, vitamin C 1mg, organic alpha rice powder 1mg, folate 0.4mg, thiamine 0.5mg, and maltodextrin 1,541mg.

Group Type PLACEBO_COMPARATOR

Micronutrient powder provided as powder

Intervention Type DIETARY_SUPPLEMENT

One sachet daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

"For Baby "supplements provided as powder

One sachet daily

Intervention Type DIETARY_SUPPLEMENT

Micronutrient powder provided as powder

One sachet daily

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Children 6-23 months of age at enrollment,
* Acceptance of weekly home visits for growth surveillance,
* Planned residency within the study area for the duration of the study period (52 weeks),
* Signed informed consent from a parent or legal caregiver.

Exclusion Criteria

* Weight-for-height z-score (WHZ) \<-3SD with respect to World Health Organization 2006 standards;
* Presence of bipedal edema;
* Severe illness warranting hospital referral;
* Congenital abnormalities potentially interfering with growth;
* Chronic medical condition (e.g., malignancy) requiring frequent medical attention;
* Known human immunodeficiency virus (HIV) infection of index child or child's mother;
* Severe anemia (hemoglobin \<70 g/L; based on testing at enrollment);
* Currently consuming MNP supplements;
* Current participation in any other clinical trial.

Criteria for discontinuation:

A subject can be discontinued from the study for the following reasons:

* Withdraws from the study (this can happen anytime as participation is voluntary and there are no further obligations).
* At the discretion of the principal investigator, if the participant is not compliant to the requirements of the protocol.
* Discontinued subjects will not be replaced. If, for any reason, a subject is discontinued from the study before the end of the evaluations, the safety procedures planned (AEs monitoring) will be conducted. Data obtained prior to subject's withdrawal will be included in analysis. Data of withdrawn patients are fully anonymized once analysis is completed.

Minimum Eligible Age

6 Months

Maximum Eligible Age

23 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No